Mesa Laboratories, Inc. (NASDAQ: MLAB) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 147.14 | EPS (ttm) | 0.86 | Insider Own | 7.51% | Shs Outstand | 5.60M | Perf Week | 4.69% |
| Market Cap | 708.10M | Forward P/E | 14.47 | EPS next Y | 8.75 | Insider Trans | -1.75% | Shs Float | 4.90M | Perf Month | 5.70% |
| Enterprise Value | 778.76M | PEG | - | EPS next Q | 1.59 | Inst Own | - | Short Float | 8.85% | Perf Quarter | 33.06% |
| Income | 4.74M | P/S | 2.84 | EPS this Y | 802.78% | Inst Trans | - | Short Ratio | 2.24 | Perf Half Y | 53.34% |
| Sales | 249.72M | P/B | 3.79 | EPS next Y | 15.34% | ROA | 1.15% | Short Interest | 433.98K | Perf YTD | 61.20% |
| Book/sh | - | P/C | 12.86 | EPS next 5Y | - | ROE | 2.59% | 52W High | 132.70 -4.64% | Perf Year | 94.23% |
| Cash/sh | - | P/FCF | 12.62 | EPS past 3/5Y | 92.36% 13.59% | ROIC | 3.05% | 52W Low | 63.48 99.34% | Perf 3Y | 2.99% |
| Dividend Est. | 0.64 (0.51%) | EV/EBITDA | 19.19 | Sales past 3/5Y | 4.37% 13.19% | Gross Margin | 65.99% | Volatility | 3.37% 3.47% | Perf 5Y | -52.79% |
| Dividend TTM | 0.64 (0.51%) | EV/Sales | 3.12 | EPS Y/Y TTM | 333.33% | Oper. Margin | 9.00% | ATR (14) | 4.71 | Perf 10Y | 9.76% |
| Dividend Ex-Date | Aug 31, 2026 | Quick Ratio | 1.52 | Sales Y/Y TTM | 3.73% | Profit Margin | 1.92% | RSI (14) | 59.55 | Recom | 2.63 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 2.07 | EPS Q/Q | 20.18% | SMA20 | 0.48% | Beta | 1.04 | Target Price | 110.00 |
| Payout | 73.63% | Debt/Eq | 0.54 | Sales Q/Q | 0.00% | SMA50 | 13.01% | Rel Volume | 0.82 | Prev Close | 127.14 |
| Employees | 717 | LT Debt/Eq | 0.86 | Earnings | Nov 05 | SMA200 | 30.81% | Avg Volume | 165.65K | Price | 126.54 |
| IPO Date | Feb 29, 1984 | Option/Short | No / Yes | EPS/Sales Surpr. | 2.10% -1.20% | Net Debt/EBITDA | 1.74 | Volume | 136,636 | Change | -0.47% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-14-26 | Reiterated | Wells Fargo | Equal Weight | $94 → $110 |
| Feb-04-26 | Reiterated | Wells Fargo | Equal Weight | $83 → $94 |
| Dec-15-25 | Reiterated | Wells Fargo | Equal Weight | $120 → $83 |
| Aug-08-25 | Upgrade | Wells Fargo | Underweight → Equal Weight | |
| Aug-27-24 | Initiated | Wells Fargo | Underweight | $120 |
| Jun-07-24 | Reiterated | Evercore ISI | Outperform | $120 |
| Jan-04-24 | Upgrade | Evercore ISI Group | In Line → Outperform | |
| Jan-04-21 | Downgrade | Evercore ISI Group | Outperform → In Line | |
| Jun-10-16 | Downgrade | Sidoti & Co. | Buy → Neutral |
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 250 | 249 | 241 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 84 | 91 | 90 | — | — | — | — | — | — | |
| Gross Profit | 165 | 158 | 151 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 108 | 119 | 115 | — | — | — | — | — | — | |
| Research and Development | 20 | 20 | 20 | — | — | — | — | — | — | |
| Other Operating Expense | 15 | 1 | 0 | — | — | — | — | — | — | |
| Operating Income | 23 | 19 | 16 | — | — | — | — | — | — | |
| Interest Expense | 11 | 11 | 12 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | 4 | 1 | — | — | — | — | — | — | |
| Net Income Before Taxes | 9 | 12 | 6 | — | — | — | — | — | — | |
| Income Taxes | 6 | 5 | 8 | — | — | — | — | — | — | |
| Consolidated Net Income | 5 | 7 | -2 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 5 | 7 | -2 | — | — | — | — | — | — | |
| Net Income | 5 | 7 | -2 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.86 | 1.22 | -0.36 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.86 | 1.22 | -0.36 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.84 | 1.21 | -0.36 | — | — | — | — | — | — | |
| EBITDA | 40 | 35 | 42 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 150.64 | 73.07 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.04 | 2.13 | 2.46 | — | — | — | — | — | — | |
| Gross Margin | 66.00 | 63.45 | 62.66 | — | — | — | — | — | — | |
| Operating Margin | 9.20 | 7.63 | 6.64 | — | — | — | — | — | — | |
| Net Margin | 2.00 | 2.81 | -0.83 | — | — | — | — | — | — | |
| Shares Outstanding | 6 | 6 | 5 | — | — | — | — | — | — | |
| Market Capitalization | 759 | 531 | 593 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ladiwala Shiraz Shabanali | Director | Aug 15 '26 | Option Exercise | 0.00 | 3,810 | 0 | 12,333 | Aug 17 |
| Capone Mark Christopher | Director | Aug 15 '26 | Option Exercise | 0.00 | 2,784 | 0 | 6,213 | Aug 17 |
| Alltoft Jennifer Sadie | Director | Aug 15 '26 | Option Exercise | 0.00 | 2,784 | 0 | 7,662 | Aug 17 |
| Hall Shannon | Director | Aug 15 '26 | Option Exercise | 0.00 | 2,784 | 0 | 6,973 | Aug 17 |
| Tripeny R Tony | Director | Aug 15 '26 | Option Exercise | 0.00 | 2,784 | 0 | 9,082 | Aug 17 |
| Sullivan John James | Director | Aug 15 '26 | Option Exercise | 0.00 | 2,784 | 0 | 20,618 | Aug 17 |
| Sullivan John James | Director | Aug 13 '26 | Sale | 112.80 | 7,093 | 800,090 | 17,834 | Aug 17 |
| Kadia Siddhartha | President and CEO | Aug 13 '26 | Buy | 112.80 | 7,093 | 800,090 | 7,093 | Aug 17 |
| Tripeny R Tony | Director | Aug 13 '26 | Buy | 113.69 | 900 | 102,321 | 6,298 | Aug 17 |
| Crennen Lyndsey Elizabeth | CAO | Jun 22 '26 | Sale | 89.50 | 442 | 39,560 | 2,020 | Jun 23 |
| Archbold Brian David | SVP Operations | Jun 22 '26 | Sale | 89.50 | 2,516 | 225,187 | 6,377 | Jun 23 |
| Sakys John | CFO | Jun 22 '26 | Sale | 89.50 | 2,827 | 253,022 | 19,785 | Jun 23 |
| Crennen Lyndsey Elizabeth | CAO | Jun 18 '26 | Option Exercise | 95.10 | 726 | 69,043 | 2,199 | Jun 23 |
| Archbold Brian David | SVP Operations | Jun 18 '26 | Option Exercise | 95.10 | 3,324 | 316,112 | 7,034 | Jun 23 |
| Sakys John | CFO | Jun 18 '26 | Option Exercise | 95.10 | 3,792 | 360,620 | 20,330 | Jun 23 |